Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02523014 · ClinicalTrials.gov registry record · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
A Phase 2 study of Recurrent Meningioma and Intracranial Meningioma, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT02523014 is a Phase 2 study of Recurrent Meningioma and Intracranial Meningioma that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 124 participants, above the 33-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (276% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT02523014, a Phase 2 study of Recurrent Meningioma and Intracranial Meningioma, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Vismodegib
- DRUG Capivasertib
- DRUG FAK Inhibitor GSK2256098
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Saint Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic in Arizona - Scottsdale
- Arizona Oncology Services Foundation - Scottsdale
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- CARTI Cancer Center - Little Rock
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02523014
The ClinicalTrials.gov registry entry for NCT02523014 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 33-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (276% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Meningioma appearing as the primary indexed condition, and to 4 interventions - of which Abemaciclib is the first listed.
NCT02523014 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Alaska, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02523014 about?
NCT02523014 is a clinical study titled "Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas". This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the g...
What is the current status of trial NCT02523014?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2015-09-28. Estimated completion is 2028-01.
What conditions does trial NCT02523014 study?
This clinical trial studies the following conditions: Recurrent Meningioma, Intracranial Meningioma, NF2 Gene Mutation.
What interventions are being tested in trial NCT02523014?
The interventions under investigation include: Abemaciclib (DRUG), Vismodegib (DRUG), Capivasertib (DRUG), FAK Inhibitor GSK2256098 (DRUG).
Who is sponsoring clinical trial NCT02523014?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02523014 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
RECRUITING · Phase 2
-
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
RECRUITING · Phase 2
-
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
RECRUITING · Phase 2
-
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
RECRUITING · NA
-
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
RECRUITING · Phase 1
-
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.